Observational studyBMC cancer2022

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.

Alfonso Yubero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.